Search alternatives:
decrease therapeutic » increased therapeutic (Expand Search), degrader therapeutics (Expand Search), great therapeutic (Expand Search)
new therapeutic » novel therapeutic (Expand Search), _ therapeutic (Expand Search)
high resistance » host resistance (Expand Search)
decrease high » decreased hiv (Expand Search), decrease i (Expand Search)
Showing 121 - 140 results of 10,552 for search '(( ((decrease therapeutic) OR (new therapeutic)) research ) OR ( decrease high resistance ))', query time: 0.78s Refine Results
  1. 121
    Supplementary Figure S5 from Mitochondria-Targeted Doxorubicin: A New Therapeutic Strategy against Doxorubicin-Resistant Osteosarcoma

    Supplementary Figure S5 from Mitochondria-Targeted Doxorubicin: A New Therapeutic Strategy against Doxorubicin-Resistant Osteosarcoma by Ilaria Buondonno (2211751)

    Published 2023
    Save to List
    Saved in:
  2. 122
    Supplementary Figure S1 from Mitochondria-Targeted Doxorubicin: A New Therapeutic Strategy against Doxorubicin-Resistant Osteosarcoma

    Supplementary Figure S1 from Mitochondria-Targeted Doxorubicin: A New Therapeutic Strategy against Doxorubicin-Resistant Osteosarcoma by Ilaria Buondonno (2211751)

    Published 2023
    Save to List
    Saved in:
  3. 123
    Supplementary Figure S4 from Mitochondria-Targeted Doxorubicin: A New Therapeutic Strategy against Doxorubicin-Resistant Osteosarcoma

    Supplementary Figure S4 from Mitochondria-Targeted Doxorubicin: A New Therapeutic Strategy against Doxorubicin-Resistant Osteosarcoma by Ilaria Buondonno (2211751)

    Published 2023
    Save to List
    Saved in:
  4. 124
    Table1_New regulation on medical devices made of substances: Opportunities and challenges for pharmacological and toxicological research.DOCX

    Table1_New regulation on medical devices made of substances: Opportunities and challenges for pharmacological and toxicological research.DOCX by Carmela Fimognari (325456)

    Published 2022
    Save to List
    Saved in:
  5. 125
    Table1_New regulation on medical devices made of substances: Opportunities and challenges for pharmacological and toxicological research.DOCX

    Table1_New regulation on medical devices made of substances: Opportunities and challenges for pharmacological and toxicological research.DOCX by Carmela Fimognari (325456)

    Published 2024
    Save to List
    Saved in:
  6. 126
    Table_1_Cardiomyocyte Protection by Hibernating Brown Bear Serum: Toward the Identification of New Protective Molecules Against Myocardial Infarction.pdf

    Table_1_Cardiomyocyte Protection by Hibernating Brown Bear Serum: Toward the Identification of New Protective Molecules Against Myocardial Infarction.pdf by Lucas Givre (11143575)

    Published 2021
    “…Therefore, the bear serum may be a potential source for identifying new therapeutic molecules to fight against myocardial reperfusion injury and cell death in general.…”
    Save to List
    Saved in:
  7. 127
    Supplementary Table from GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis

    Supplementary Table from GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis by Shaina F. Bruce (15091273)

    Published 2023
    Save to List
    Saved in:
  8. 128
    Supplementary Figure from GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis

    Supplementary Figure from GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis by Shaina F. Bruce (15091273)

    Published 2023
    Save to List
    Saved in:
  9. 129
    Supplementary Figure from GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis

    Supplementary Figure from GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis by Shaina F. Bruce (15091273)

    Published 2023
    Save to List
    Saved in:
  10. 130
    Supplementary Figure from GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis

    Supplementary Figure from GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis by Shaina F. Bruce (15091273)

    Published 2023
    Save to List
    Saved in:
  11. 131
    Supplementary Table from GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis

    Supplementary Table from GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis by Shaina F. Bruce (15091273)

    Published 2023
    Save to List
    Saved in:
  12. 132
    Supplementary Table from GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis

    Supplementary Table from GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis by Shaina F. Bruce (15091273)

    Published 2023
    Save to List
    Saved in:
  13. 133
    Supplementary Figure from GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis

    Supplementary Figure from GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis by Shaina F. Bruce (15091273)

    Published 2023
    Save to List
    Saved in:
  14. 134
    Supplementary Figure from GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis

    Supplementary Figure from GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis by Shaina F. Bruce (15091273)

    Published 2023
    Save to List
    Saved in:
  15. 135
    Supplementary Data S1 from SAM-Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance

    Supplementary Data S1 from SAM-Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance by Kristen Jensen-Pergakes (15090247)

    Published 2023
    Save to List
    Saved in:
  16. 136
    Supplementary Data S2 from SAM-Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance

    Supplementary Data S2 from SAM-Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance by Kristen Jensen-Pergakes (15090247)

    Published 2023
    Save to List
    Saved in:
  17. 137
    Supplementary Data S3 from SAM-Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance

    Supplementary Data S3 from SAM-Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance by Kristen Jensen-Pergakes (15090247)

    Published 2023
    Save to List
    Saved in:
  18. 138
    Major research and development steps required for development of a therapeutic product from HPE/constituent AMPPs.

    Major research and development steps required for development of a therapeutic product from HPE/constituent AMPPs. by Kate Summer (20592229)

    Published 2025
    Save to List
    Saved in:
  19. 139
    Supplementary Tables S2A and S2B from Cytidine Deaminase Deficiency Reveals New Therapeutic Opportunities against Cancer

    Supplementary Tables S2A and S2B from Cytidine Deaminase Deficiency Reveals New Therapeutic Opportunities against Cancer by Hamza Mameri (1560091)

    Published 2023
    Save to List
    Saved in:
  20. 140
    Supplementary Figures 1-8 from Targeting Notch Signaling with a Notch2/Notch3 Antagonist (Tarextumab) Inhibits Tumor Growth and Decreases Tumor-Initiating Cell Frequency

    Supplementary Figures 1-8 from Targeting Notch Signaling with a Notch2/Notch3 Antagonist (Tarextumab) Inhibits Tumor Growth and Decreases Tumor-Initiating Cell Frequency by Wan-Ching Yen (11520727)

    Published 2023
    Save to List
    Saved in:

Search Tools: